120 related articles for article (PubMed ID: 16520661)
21. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Richard CL; Blay J
Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024
[TBL] [Abstract][Full Text] [Related]
22. Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.
Guo YT; Leng XS; Li T; Peng JR; Song SH; Xiong LF; Qin ZZ
World J Gastroenterol; 2005 Aug; 11(30):4735-9. PubMed ID: 16094720
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
24. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
[TBL] [Abstract][Full Text] [Related]
25. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
26. Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
Wei R; Yu F; Yang J; Gao H; Wang H; Hong T
Cell Biol Int; 2018 May; 42(5):515-524. PubMed ID: 29274299
[TBL] [Abstract][Full Text] [Related]
27. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375.
Liu Y; Meng Y; Li H; Li J; Fu J; Liu Y; Chen XG
Med Oncol; 2006; 23(3):393-402. PubMed ID: 17018897
[TBL] [Abstract][Full Text] [Related]
28. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.
Xiong X; Ye Y; Fu L; Dai B; Liu J; Jia J; Tang J; Li L; Wang L; Shen J; Mei C
Invest New Drugs; 2009 Jun; 27(3):223-32. PubMed ID: 18704263
[TBL] [Abstract][Full Text] [Related]
31. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
32. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
33. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
34. Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells.
Cellai I; Benvenuti S; Luciani P; Galli A; Ceni E; Simi L; Baglioni S; Muratori M; Ottanelli B; Serio M; Thiele CJ; Peri A
Br J Cancer; 2006 Oct; 95(7):879-88. PubMed ID: 16969347
[TBL] [Abstract][Full Text] [Related]
35. PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.
Dana N; Vaseghi G; Haghjooy Javanmard S
J Pharm Pharm Sci; 2019; 22(1):418-423. PubMed ID: 31509504
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
Polikandriotis JA; Mazzella LJ; Rupnow HL; Hart CM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1810-6. PubMed ID: 16020752
[TBL] [Abstract][Full Text] [Related]
38. A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
Kobuke T; Tazuma S; Hyogo H; Chayama K
Dig Dis Sci; 2006 Sep; 51(9):1650-7. PubMed ID: 16927143
[TBL] [Abstract][Full Text] [Related]
39. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of PPARgamma ligands on oxidative stress-induced death of retinal pigmented epithelial cells.
Rodrigues GA; Maurier-Mahé F; Shurland DL; McLaughlin A; Luhrs K; Throo E; Delalonde-Delaunay L; Pallares D; Schweighoffer F; Donello J
Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):890-903. PubMed ID: 20847119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
